CVRx Inc
Research CVRx Inc (CVRX) on Bullrun: market cap USD 89.78M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCVRX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Market capUSD 89.78M
- Financial periodQ2 2026
- RevenueUSD 15.71M
- Net income-USD 14.04M
- Free cash flow-USD 8.94M
- Gross margin87.4%
Valuation Snapshot
latest market cap is USD 89.78M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 56.65M | -USD 53.31M | -USD 40.75M | 85.3% | -2.04 | USD 75.71M | USD 49.51M | USD 39.32M |
| FY2024 | USD 51.29M | -USD 59.97M | -USD 40.51M | 83.8% | -2.65 | USD 105.93M | USD 49.27M | USD 71.06M |
| FY2023 | USD 39.30M | -USD 41.20M | -USD 39.61M | 84.1% | -1.99 | USD 90.57M | USD 29.22M | USD 75.95M |
| FY2022 | USD 22.47M | -USD 41.43M | -USD 43.36M | 77.8% | -2.02 | USD 106.19M | USD 6.75M | USD 109.18M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 89.78M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 186.81M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 320.86M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 654.44M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 377.72M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 249.48M | n/a | n/a | n/a |
About CVRx Inc
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CVRx Inc's market cap?
CVRx Inc's market capitalization is USD 89.78M.
What does CVRx Inc do?
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system.